MedPath

SOLARIS Peripheral PMCF Trial

Not Applicable
Active, not recruiting
Conditions
Iliac Artery Stenosis
Peripheral Arterial Disease
Common Femoral Artery Stenosis
Interventions
Device: Solaris Vascular Stent Graft
Registration Number
NCT04299906
Lead Sponsor
Dr. Sabrina Overhagen
Brief Summary

The objective of this clinical investigation is to evaluate, in a controlled setting, the long-term (up to 12 months) safety and efficacy of the Solaris Vascular Stent Graft (Scitech) in clinical settings when used according to the indications of the IFU.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
70
Inclusion Criteria
  • Corresponding to the IFU indications/contra-indications and according to the current medical guidelines for minimally invasive peripheral interventions.
  • Patient presenting with a stenotic or occlusive lesion at the iliac arteries suitable for stenting (on indication for primary stenting, based on the discretion of the investigator)
  • Patient presenting a score from 2 to 5 following Rutherford classification
  • Patient is willing to comply with specified follow-up evaluations at the specified times for the duration of the study
  • Patient is >18 years old
  • Patient (or their legal representative) understands the nature of the procedure and provides written informed consent, prior to enrolment in the study
  • The target lesion is either a modified TASC-II class A, B, C or D lesion.
  • The target lesion has angiographic evidence of stenosis or restenosis > 50% or occlusion which can be passed with standard guidewire manipulation
  • There is angiographic evidence of a patent Common and Deep Femoral Artery
Exclusion Criteria
  • PTA is technically not possible (not feasible to access the lesion or a defect with the guidewire or balloon catheter)
  • Presence of an aneurysm immediately adjacent to the site of stent implantation
  • Stenosis distal to the site of stent implantation
  • Lesions in or adjacent to essential collaterals(s)
  • Lesions in locations subject to external compression
  • Heavily calcified lesions resistant to PTA
  • Patients with diffuse distal disease resulting in poor stent outflow
  • Patients with a history of coagulation disorders
  • Patients with aspirin allergy or bleeding complications and patients unable or unwilling to tolerate anticoagulant/antiplatelet therapy and/or non-responders to anticoagulant/antiplatelet therapy
  • Fresh thrombus formation
  • Patients with known hypersensitivity to the stent material (L605) and/or PTFE
  • The target lesion is either a modified TASC-II class B or D lesion with aortic or common femoral lesion involvement.
  • Previously implanted stent(s) at the same lesion site
  • Reference segment diameter is not suitable for the available stent design
  • Untreatable lesion located at the distal outflow arteries
  • Use of alternative therapy (e.g. atherectomy, cutting balloon, laser, radiation therapy) as part of the index procedure
  • Patients refusing treatment
  • Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated
  • Patients who exhibit persistent acute intraluminal thrombus of the proposed lesion site
  • Perforation at the angioplasty site evidenced by extravasation of contrast medium
  • Patients with a history of prior life-threatening contrast medium reaction
  • Patients with uncorrected bleeding disorders
  • Female patient with child bearing potential not taking adequate contraceptives or currently breastfeeding
  • Life expectancy of less than twelve months
  • Any planned surgical intervention/procedure within 30 days of the study procedure
  • Any patient considered to be hemodynamically unstable at onset of procedure
  • Patient is currently participating in another investigational drug or device study that has not completed the entire follow up period.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Solaris Vascular Stent GraftSolaris Vascular Stent GraftImplant of Solaris Vascular Stent Graft in aorto-iliac lesions
Primary Outcome Measures
NameTimeMethod
Primary Patency Rate at 12 month follow-up12 months post-op
Secondary Outcome Measures
NameTimeMethod
Stent Graft Occlusion Rate at pre-discharge, 1-, 6-, and 12-month follow-up1day, 1 month, 6 month and 12 month post-op
Ankle-Brachial Index at 1-, 6- and 12-month follow-up compared with baseline ABI1-, 6- and 12-month post-op
Primary Patency Rate at 1- and 6 month follow-up1 monthand 6 months post-op
in-stent restenosis rate at 1-, 6- and 12-month post-op1-, 6-, 12-month post-op
Performance success rate at baselineduring procedure

defined as a composite of (a) successful in sealing acute perforation or rupture; (b) successful in treating aneurysm and fistulae ; (c) restoration of blood flow

Freedom from Target Lesion Revascularization at 1-, 6- and 12-month post-op1-, 6- and 12-month post-op

defined as freedom from a repeat intervention to maintain or re-establish patency within the region of the treated arterial vessel plus 5mm proximal and distal to the treated lesion edge

Technical success rateduring procedure

defined as the ability to achieve final residual angiographic stenosis no greater than 30%

Clinical success at follow-up1-, 6- and 12-month post-op

defined as an improvement of Rutheford Classification at 1-, 6- and 12-month follow-up of one class or more as compared to the pre-procedure Rutherford classification

Amputation rate at 1-, 6- and 12-month follow-up, defined as any amputation above the knee1-, 6- and 12-month post-op
Serious Adverse Events (SAE's) until 12-month post-opwithin 12-months post-op

Trial Locations

Locations (10)

Hospital Hochsauerland

🇩🇪

Arnsberg, Germany

University Hospital Leipzig

🇩🇪

Leipzig, Germany

Saarland University Medical Center

🇩🇪

Homburg, Germany

Hospital Oldenburg

🇩🇪

Oldenburg, Germany

University Hospital Münster

🇩🇪

Münster, Germany

Azienda Ospedaliera di Perugia

🇮🇹

Perugia, Italy

Fondazione Policlinico Gemelli

🇮🇹

Rom, Italy

St. Franziskus Hospital

🇩🇪

Münster, Germany

MCL Leeuwarden

🇳🇱

Leeuwarden, Netherlands

St. Antonius Hospital

🇳🇱

Nieuwegein, Netherlands

© Copyright 2025. All Rights Reserved by MedPath